Background/Aims: Octreotide acutely decreases splanchnic blood flow and postprandial portal pressure in patients with portal hypertension. Inhibition of glucagon release parallels the hemodynamic changes. We studied the hormonal and renal effects of long-term treatment with octreotide (100 μg s.c., t.i.d., immediately before meals, for 2 weeks) in 12 patients with cirrhosis and portal hypertension. Methods: Postprandial blood levels of glucagon, insulin and glucose, and renal function tests were monitored in a study where patients acted as their own controls. Eleven patients completed the study, octreotide being discontinued in one patient who developed jaundice after 6 days of therapy. Results: Long-term treatment did not cause any change in fasting hormonal levels measured 12 h after the last injection of octreotide. However, pre-prandial injection of octreotide induced a marked fall in blood glucagon (163 ± 49 pg/ml, after 20 min, vs. 254 ± 71 pg/ml, basal; p < 0.01), thus preventing the postprandial response occurring without treatment (322 ± 102 pg/ml, 30 min-peak, vs. 249 ± 77 pg/ml, basal; p < 0.03). Inhibition of postprandial glucagon was maintained after 2 weeks of therapy (159 ± 33 pg/ml, after 20 min, vs. 237 ± 54 pg/ml, basal; p < 0.01). Octreotide abolished the insulin postprandial response with no major change in glycemic control. Treatment had no long-term effect on renal plasma flow (effective renal plasma flow: 596 ± 79 ml/min, baseline, vs. 609 ± 71 ml/min, at 2 weeks; p > 0.5), glomerular filtration rate (glomerular filtration rate: 99 ± 11 vs. 99 ± 12 ml/min; p > 0.5), blood urea and creatinine, whereas it induced a mild decrease in plasma electrolyte levels (p < 0.02). Conclusions: Long-term octreotide treatment persistently suppresses the postprandial glucagon response of patients with portal hypertension without causing deterioration in their renal function.

Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function / A. Malesci, M. Tacconi, A. Valentini, M. Basilico, E. Lorenzano, F. Salerno. - In: JOURNAL OF HEPATOLOGY. - ISSN 0168-8278. - 26:4(1997 Apr), pp. 816-825.

Octreotide long-term treatment in patients with portal hypertension: persistent inhibition of postprandial glucagon response without major changes in renal function

A. Malesci
Primo
;
1997

Abstract

Background/Aims: Octreotide acutely decreases splanchnic blood flow and postprandial portal pressure in patients with portal hypertension. Inhibition of glucagon release parallels the hemodynamic changes. We studied the hormonal and renal effects of long-term treatment with octreotide (100 μg s.c., t.i.d., immediately before meals, for 2 weeks) in 12 patients with cirrhosis and portal hypertension. Methods: Postprandial blood levels of glucagon, insulin and glucose, and renal function tests were monitored in a study where patients acted as their own controls. Eleven patients completed the study, octreotide being discontinued in one patient who developed jaundice after 6 days of therapy. Results: Long-term treatment did not cause any change in fasting hormonal levels measured 12 h after the last injection of octreotide. However, pre-prandial injection of octreotide induced a marked fall in blood glucagon (163 ± 49 pg/ml, after 20 min, vs. 254 ± 71 pg/ml, basal; p < 0.01), thus preventing the postprandial response occurring without treatment (322 ± 102 pg/ml, 30 min-peak, vs. 249 ± 77 pg/ml, basal; p < 0.03). Inhibition of postprandial glucagon was maintained after 2 weeks of therapy (159 ± 33 pg/ml, after 20 min, vs. 237 ± 54 pg/ml, basal; p < 0.01). Octreotide abolished the insulin postprandial response with no major change in glycemic control. Treatment had no long-term effect on renal plasma flow (effective renal plasma flow: 596 ± 79 ml/min, baseline, vs. 609 ± 71 ml/min, at 2 weeks; p > 0.5), glomerular filtration rate (glomerular filtration rate: 99 ± 11 vs. 99 ± 12 ml/min; p > 0.5), blood urea and creatinine, whereas it induced a mild decrease in plasma electrolyte levels (p < 0.02). Conclusions: Long-term octreotide treatment persistently suppresses the postprandial glucagon response of patients with portal hypertension without causing deterioration in their renal function.
glucagon release; glycemic homeostasis; octreotide; portal hypertension; renal function; splanchnic hemodynamics
Settore MED/12 - Gastroenterologia
Settore MED/09 - Medicina Interna
apr-1997
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0168827897802474-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 798.7 kB
Formato Adobe PDF
798.7 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/226356
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 25
  • ???jsp.display-item.citation.isi??? 22
social impact